PepGen Inc. (PEPG) stock forecast & analysis
4.69
NasdaqGS · USDDelayed by 15 minutes
Down: -0.35, -7.1%
1 analysis
Latest analysis: · verdict locked
- Open
- 5.05
- Previous close
- 5.04
- Day range
- 4.57 – 5.05
- 52-week range
- 1.31 – 7.80
- Volume (shares)
- 533.85K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 69.26M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- Not available
- Market cap
- 324.50M
Market Scanner’s AI analysis of PepGen Inc. (PEPG), updated November 2026: PepGen's stock price surged following positive Phase 2 trial data for its DMD drug, leading to significant market attention and a proposed public offering.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of PepGen Inc. (PEPG) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
PepGen's stock price surged following positive Phase 2 trial data for its DMD drug, leading to significant market attention and a proposed public offering.
Recent analyses covered PepGen's substantial stock price increase, driven by positive Phase 2 clinical trial results for its Duchenne Muscular Dystrophy drug. The company announced a strong cash position alongside a proposed public offering to capitalize on its current valuation.
PEPG news & sentiment
News reports highlighted significant positive market reactions to PepGen's promising clinical trial data, driving a substantial stock price increase. Social media discussions reflected this positive momentum, with high engagement around the company's recent developments.
PEPG technical picture
PEPG's price action showed significant upward momentum, trading well above its 50-day and 200-day SMAs. Momentum indicators suggested strong buying pressure and bullish momentum, though readings indicated the stock may be overextended and trading in overbought territory above the upper Bollinger Band.
Fundamentals
PepGen has consistently reported net losses and operating losses over the past several years and through the first three quarters of 2026. The company's market capitalization was approximately $319 million as of June 30, 2026, with a stock price of $4.61 and a 52-week range of $1.31 to $7.80.
Factors discussed — upside
- Positive Phase 2 trial results for Duchenne Muscular Dystrophy drug (FREEDOM2-DM1)
- Significant stock price increase, with reports of over 100% surge
- Strong cash position reported at $104.8 million as of Q3 2026
- Stock price trading well above 50-day and 200-day SMAs, indicating a strong uptrend
- High MFI and MACD values suggesting strong buying pressure and bullish momentum
Factors discussed — risks
- Consistent net losses reported annually and quarterly
- RSI and MFI indicating the stock may be overextended in the short term
- Stock price trading above the upper Bollinger Band, suggesting overbought conditions
- High Beta of 2.017 indicating higher volatility than the market
- Clinical trial data
- Stock price momentum
- Financial performance
- Capital raising
Summary updated .
PEPG technical indicators
Common technical indicators for PEPG, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.80 | Price above |
| 10-day exponential moving average | 3.79 | Price above |
| Relative strength index (14-day) | 71.60 | Overbought |
| MACD line (12/26/9) | 0.5002 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 1.06 – 4.93 | Price inside the bands |
Analyses
Recent PEPG.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-11 PEPG.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for PepGen Inc.?
- The bull case centers on positive Phase 2 trial results for PepGen's Duchenne Muscular Dystrophy drug, which has driven a significant stock price increase and demonstrated strong buying momentum. The company also reported a robust cash position and is trading above key moving averages, indicating a strong uptrend.
- What are the risks for PepGen Inc.?
- The bear case highlights PepGen's history of consistent net losses and the current stock price potentially being overextended, as indicated by high RSI and MFI readings and trading above the upper Bollinger Band. The company's high Beta also suggests increased volatility relative to the broader market.
- Is PepGen Inc. bullish or bearish?
- Recent AI analyses of PepGen Inc. examined factors on both sides. Discussed upside: The bull case centers on positive Phase 2 trial results for PepGen's Duchenne Muscular Dystrophy drug, which has driven a significant stock price increase and demonstrated strong buying momentum. The company also reported a robust cash position and is trading above key moving averages, indicating a strong uptrend. Discussed risks: The bear case highlights PepGen's history of consistent net losses and the current stock price potentially being overextended, as indicated by high RSI and MFI readings and trading above the upper Bollinger Band. The company's high Beta also suggests increased volatility relative to the broader market. These are descriptive observations, not a recommendation.
- What is the latest sentiment on PepGen Inc.?
- News reports highlighted significant positive market reactions to PepGen's promising clinical trial data, driving a substantial stock price increase. Social media discussions reflected this positive momentum, with high engagement around the company's recent developments.
- How does Market Scanner analyse PepGen Inc.?
- Every analysis of PepGen Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for PepGen Inc.?
The bull case centers on positive Phase 2 trial results for PepGen's Duchenne Muscular Dystrophy drug, which has driven a significant stock price increase and demonstrated strong buying momentum. The company also reported a robust cash position and is trading above key moving averages, indicating a strong uptrend.
What are the risks for PepGen Inc.?
The bear case highlights PepGen's history of consistent net losses and the current stock price potentially being overextended, as indicated by high RSI and MFI readings and trading above the upper Bollinger Band. The company's high Beta also suggests increased volatility relative to the broader market.
Is PepGen Inc. bullish or bearish?
Recent AI analyses of PepGen Inc. examined factors on both sides. Discussed upside: The bull case centers on positive Phase 2 trial results for PepGen's Duchenne Muscular Dystrophy drug, which has driven a significant stock price increase and demonstrated strong buying momentum. The company also reported a robust cash position and is trading above key moving averages, indicating a strong uptrend. Discussed risks: The bear case highlights PepGen's history of consistent net losses and the current stock price potentially being overextended, as indicated by high RSI and MFI readings and trading above the upper Bollinger Band. The company's high Beta also suggests increased volatility relative to the broader market. These are descriptive observations, not a recommendation.
What is the latest sentiment on PepGen Inc.?
News reports highlighted significant positive market reactions to PepGen's promising clinical trial data, driving a substantial stock price increase. Social media discussions reflected this positive momentum, with high engagement around the company's recent developments.
How does Market Scanner analyse PepGen Inc.?
Every analysis of PepGen Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh PEPG.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.